NDC 0310-4700

LUMOXITI

Moxetumomab Pasudotox

LUMOXITI is a Intravenous Injection, Powder, Lyophilized, For Solution in the Human Prescription Drug category. It is labeled and distributed by Astrazeneca Pharmaceuticals Lp. The primary component is Moxetumomab Pasudotox.

Product ID0310-4700_3c0aedca-0378-43ce-adcf-0b1caf0da3be
NDC0310-4700
Product TypeHuman Prescription Drug
Proprietary NameLUMOXITI
Generic NameMoxetumomab Pasudotox
Dosage FormInjection, Powder, Lyophilized, For Solution
Route of AdministrationINTRAVENOUS
Marketing Start Date2018-10-24
Marketing CategoryBLA / BLA
Application NumberBLA761104
Labeler NameAstraZeneca Pharmaceuticals LP
Substance NameMOXETUMOMAB PASUDOTOX
Active Ingredient Strength1 mg/mL
NDC Exclude FlagN
Listing Certified Through2021-12-31

Packaging

NDC 0310-4700-01

1 VIAL in 1 CARTON (0310-4700-01) > 1 mL in 1 VIAL
Marketing Start Date2018-10-24
NDC Exclude FlagN
Sample Package?N

NDC SPL Data Element Entries

NDC 0310-4700-01 [00310470001]

LUMOXITI INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
Marketing CategoryBLA
Application NumberBLA761104
Product TypeHUMAN PRESCRIPTION DRUG
Billing UnitEA
Marketing Start Date2018-10-24

Drug Details

Active Ingredients

IngredientStrength
MOXETUMOMAB PASUDOTOX1 mg/mL

OpenFDA Data

SPL SET ID:d6510282-1a57-4614-9859-299a227a089c
Manufacturer
UNII
RxNorm Concept Unique ID - RxCUI
  • 2099314
  • 2099309
  • NDC Crossover Matching brand name "LUMOXITI" or generic name "Moxetumomab Pasudotox"

    NDCBrand NameGeneric Name
    0310-4700LUMOXITImoxetumomab pasudotox
    73380-4700LUMOXITIMOXETUMOMAB PASUDOTOX

    Trademark Results [LUMOXITI]

    Mark Image

    Registration | Serial
    Company
    Trademark
    Application Date
    LUMOXITI
    LUMOXITI
    87778486 5610169 Live/Registered
    INNATE PHARMA S.A.
    2018-01-31

    © 2024 FDA.report
    This site is not affiliated with or endorsed by the FDA.